Meloxicam/rizatriptan
Appearance
Combination of | |
---|---|
Meloxicam | Nonsteroidal anti-inflammatory drug |
Rizatriptan | serotonin (5-HT) 1B/1D receptor agonist (triptan) |
Clinical data | |
Trade names | Symbravo |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
KEGG |
Meloxicam/rizatriptan, sold under the brand name Symbravo, is a fixed-dose combination medication used for the treatment of migraine.[1] It is a combination of meloxicam, a nonsteroidal anti-inflammatory medication; and rizatriptan (as rizatriptan benzoate), a serotonin (5-HT) 1B/1D receptor agonist (triptan).[1] It is taken by mouth.[1]
Meloxicam/rizatriptan was approved for medical use in the United States in January 2025.[2]
Medical uses
[edit]Meloxicam/rizatriptan is indicated for the acute treatment of migraine with or without aura in adults.[1]
Society and culture
[edit]Legal status
[edit]Meloxicam/rizatriptan was approved for medical use in the United States in January 2025.[2]
References
[edit]- ^ a b c d e https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215431s000lbl.pdf
- ^ a b "Axsome Therapeutics Announces FDA Approval of Symbravo (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults" (Press release). Axsome Therapeutics. 30 January 2025. Retrieved 7 February 2025 – via GlobeNewswire.
External links
[edit]- Clinical trial number NCT03896009 for "Maximizing Outcomes in Treating Acute Migraine (MOMENTUM)" at ClinicalTrials.gov
- Clinical trial number NCT04163185 for "Initiating Early Control of Migraine Pain and Associated Symptoms (INTERCEPT)" at ClinicalTrials.gov